Delving into the Latest Updates on Beijing Anxin Huaide Biotechnology Co., Ltd with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Neoplasms

Immune System Diseases

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1
Immune System Diseases	1

Top 5 Drug Type	Count

Biological products	1

Phase Ia: Evaluate the safety and tolerability of AX-023 in subjects with relapsed or refractory lymphoma, and explore the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or recommended dose for Phase II (RP2D) of AX-023. Phase Ib: Evaluate the efficacy of AX-023 in the treatment of selected tumor types.

Start Date26 Sep 2025

Sponsor / Collaborator

Beijing Anxin Huaide Biotechnology Co., Ltd

100 Clinical Results associated with Beijing Anxin Huaide Biotechnology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Beijing Anxin Huaide Biotechnology Co., Ltd

Login to view more data

100 Deals associated with Beijing Anxin Huaide Biotechnology Co., Ltd

Login to view more data

100 Translational Medicine associated with Beijing Anxin Huaide Biotechnology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data